Amidst a fresh uptick in coronavirus cases across Andhra Pradesh, medical professionals are actively revisiting past clinical experiences to optimize patient care. Consequently, a recently published study by Kakinada-based infectious diseases specialist Dr. Yanamadala Muralikrishna has renewed interest in structured COVID-19 home treatment protocols. This research, published in the Journal of Primary Care Specialties, provides valuable insights into clinical management during the devastating Delta wave. Specifically, targeting early physiological complications can prevent mild cases from progressing to severe respiratory distress. Healthcare systems frequently faced massive shortages of oxygen and hospital beds during the peak of the pandemic. Therefore, finding reliable domiciliary treatment options became a necessity for thousands of patients. By evaluating these historical outcomes, modern primary care physicians can better understand the therapeutic pathways that keep patients safe at home.

Understanding the Triad of COVID-19 Complications

The clinical severity of SARS-CoV-2 infection often stems from three interrelated pathophysiological mechanisms. First, excessive systemic inflammation can trigger severe lung damage. Second, hypercoagulability or abnormal blood clotting increases the risk of microvascular thrombosis. Third, secondary bacterial infections can complicate viral pneumonia, worsening patient outcomes. To address this dangerous triad, Dr. Muralikrishna designed a targeted drug regimen utilizing readily available medications. Specifically, this regimen combined aspirin, prednisolone, and azithromycin to interrupt the disease process at an early stage. Aspirin was administered at 150 mg daily to combat clotting risks. Meanwhile, low-dose prednisolone was used to suppress early inflammatory surges, and azithromycin was included to prevent secondary bacterial complications. In contrast, standard state-supplied kits in 2021 focused primarily on symptomatic relief with doxycycline, ivermectin, and paracetamol. This triple-drug approach addressed the root causes of clinical deterioration rather than masking symptoms. Consequently, the study highlights how early targeted pharmacological intervention can successfully alter the natural trajectory of viral illness.

Evaluating the COVID-19 Home Treatment Protocol

The clinical research was conducted at Lakshmi Vaidyasala in Kakinada, assessing the efficacy of this early intervention. Specifically, the study evaluated outcomes among 120 adult patients diagnosed with mild COVID-19. Half of these patients received the standard government kit, while the other sixty patients underwent the specialized regimen. Consequently, the researchers compared this pathophysiology-informed COVID-19 home treatment protocol against standard care. Patients in both groups were monitored closely to ensure adherence and track symptoms. The specialized treatment group demonstrated rapid symptom resolution, with nearly all patients recovering without requiring supplementary oxygen. Conversely, those receiving standard care experienced slower recovery trajectories and higher rates of persistent fever. This comparative analysis underscores the necessity of proactive management in mild viral infections. Primary care doctors often hesitate to prescribe early anti-inflammatory or antiplatelet therapies. However, this study suggests that timely intervention under strict medical supervision can achieve excellent clinical outcomes. Furthermore, this protocol is cost-effective, making it a viable solution for resource-constrained rural areas in India.

Analyzing Clinical Outcomes and Hospitalization Rates

The primary objective of the study was to evaluate how effectively the specialized protocol reduced the need for hospital admission. Remarkably, the hospitalization rate among patients in the specialized-treatment group dropped to just 1.7%, representing only a single patient. In contrast, the standard group experienced a 13.3% hospitalization rate, with eight patients requiring admission. Therefore, the specialized triple-drug regimen achieved an impressive reduction in relative risk. During the Delta wave, hospital beds were critically scarce, and oxygen shortages created immense panic. Thus, reducing hospitalizations by nearly eightfold was of paramount clinical significance. This dramatic difference in outcomes shows that early domiciliary care is a vital strategy for preserving hospital capacity. Additionally, early recovery prevents severe respiratory failure and intensive care admissions. Primary care clinicians can utilize these findings to refine their triage and management algorithms during seasonal spikes. While newer variants are milder, early diagnosis and targeted treatment remain the best safeguards.

Mitigating the Long-Term Burden of Long-COVID

Beyond acute recovery, the study also recorded significant benefits regarding long-term post-viral complications. Many survivors continue to suffer from persistent fatigue and dry cough, known as long-COVID. Interestingly, patients receiving the specialized triple-drug regimen reported substantially fewer long-term symptoms. Specifically, the study group reported significantly lower rates of persistent fatigue at day fourteen. This reduction is due to early suppression of inflammation and clotting. When viral-induced inflammation is allowed to burn unchecked, it can cause chronic tissue damage that takes months to resolve. Furthermore, microthrombi can impair tissue perfusion, contributing to chronic fatigue. By using aspirin and prednisolone early, the protocol protected the microvasculature and minimized ongoing immune activation. Consequently, patients returned to their baseline health much faster. This finding is highly relevant for general practitioners, proving early intervention prevents complex chronic complications.

Relevance to Future Pandemic and Outbreak Preparedness

As COVID-19 cases experience periodic upticks in Andhra Pradesh and other states, these historical findings provide crucial lessons. Although modern Omicron variants differ genetically from Delta, the core pathophysiology of viral pneumonia remains consistent. Therefore, the principles of early diagnosis, appropriate medical supervision, and timely evidence-based treatment remain highly relevant. Medical experts suggest that these findings can strengthen primary healthcare responses during future infectious disease outbreaks. By demonstrating that a structured primary care protocol prevents worsening, this study offers a blueprint for decentralized management. Consequently, local clinics and family physicians can manage the vast majority of mild cases safely within the community. This approach dramatically reduces the pressure on tertiary care referral hospitals during major surges. Ultimately, the integration of targeted, pathophysiology-informed regimens into primary care guidelines can elevate the standard of community health. Clinicians must adopt such evidence-based strategies to build resilient healthcare systems.

Frequently Asked Questions

Q1: What are the primary drugs used in Dr. Muralikrishna's COVID-19 home treatment protocol?

The specialized protocol combines three primary medications: aspirin (150 mg), prednisolone (10 mg twice daily), and azithromycin (250 mg twice daily), typically administered for seven days. This combination targets three key complications: inflammation, hypercoagulability, and secondary bacterial infections. In contrast, standard kits often rely strictly on symptomatic relief with paracetamol, doxycycline, and ivermectin, which do not address early inflammatory or clotting cascades.

Q2: How significant was the reduction in hospitalization rates under this specialized regimen?

According to the peer-reviewed study, the hospitalization rate among mild COVID-19 patients dropped from 13.3% in the standard-treatment group to just 1.7% in the specialized-treatment group. This represents an eightfold reduction in hospital admissions. Consequently, this protocol demonstrates how early, targeted clinical intervention at home can successfully prevent disease progression and significantly alleviate the burden on tertiary healthcare facilities during severe viral surges.

Q3: Does the protocol offer any protection against long-COVID or post-viral complications?

Yes, the study observed that patients treated with the specialized regimen experienced significantly lower rates of post-COVID complications. Specifically, symptoms like persistent fatigue and dry cough were far less common at follow-up. This protection is attributed to early prednisolone and aspirin administration, suppressing systemic inflammation and microvascular clotting before they cause lasting tissue damage.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.

References

1. As Covid cases rise, AP doctor’s delta-wave study offers lessons - ETHealthworld


2. Muralikrishna Rao YV. Clinical Outcomes of a Pathophysiology-informed Home-care Approach during the COVID-19 Delta Wave. Journal of Primary Care Specialties. 2026;7(2):112-118.